Satisfying needs for
niche Specialty Care products
00 / pharma& news
07/04/2021
Continuing to build up our organisation, following the acquisition of Pegasys, pharma& is pleased to welcome Detlef Jakschies, PhD as Medical & Scientific Director. Detlef will be responsible for leading and implementing pharma&’s medical and scientific strategies, developing customized solutions to best serve the patients’ needs, with a focus on our worldwide business for Pegasys (Peginterferon alfa 2a).
Detlef joins us with a strong background in the field of Interferons, ranging from research at the Medical School of Hannover to various commercial roles in the pharmaceutical industry over the last 20 years, focussing on scientific leadership in the field of haematology and oncology. Respected and valued for his deep scientific understanding and clinical know-how, he is regarded as a valuable partner for his customers and peers alike and has established a strong network within the scientific community.
01 / pharma& is
pharma& is a privately owned company, aiming at satisfying needs for niche, original, Specialty Care products.
Our commitment to patient access for well-established original Specialty Care medicines and our worldwide presence of own subsidiaries, affiliated companies and partnerships, secure sustainable product availibilty in markets around the world.
02 / pharma& story
After having acquired multiple products in various therapeutic areas and having established a profound base to secure patient access and to supply products across the entire European Landscape we have expanded our footprint to serve patients around the world.
We are proud of our “every patient counts” commitment and our strong partnership network.
03 / pharma& team
All of us have been trained over decades in Top Tier Global Pharmaceutical Companies, coming together as a team, committed and enjoying to grow together.
Supported by our trusted network of highly qualified service providers and experts, we want to shape our future and to leave footprints for the benefits of our patients, their caregivers and our stakeholders.
04 / pharma& founders
05 / pharma& portfolio
05.1 / prescription medicines
05.2 / consumer health
05.3 / affiliated companies
06 / pharma& pharmacovigilance contact
IN GERMAN
Bei Nebenwirkungen wenden Sie sich bitte an
oder schreiben Sie ein Email an pv@drehm.at.
Zusätzlich können Sie auch direkt über die Homepage des Bundesamtes für Sicherheit im Gesundheitswesen (http://www.basg.gv.at) Nebenwirkungsfälle melden.
IN ENGLISH
In case of adverse events, please contact
or send an Email to pv@drehm.at.
Additionally, you can also report adverse events via your local health authorities.
IN DUTCH
Voor het melden van bijwerkingen, contacteer
of u kunt een e-mail sturen naar pharmacovigilance@bfc.nl.
Daarnaast kunt u bijwerkingen ook melden bij het Lareb, www.lareb.nl.